Last update 21 Nov 2024

Ioforminol

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Contrast agent, Small molecule drug

Synonyms

Ioforminol (USAN/INN)

+ [3]

Target-

Mechanism

Radiography enhancers

Therapeutic Areas

Cardiovascular DiseasesEndocrinology and Metabolic DiseaseUrogenital Diseases

Active Indication-

Inactive Indication

Chronic Kidney DiseasesDiabetes MellitusHeart Failure+ [1]

Originator Organization

GE Healthcare, Inc.

Active Organization-

Inactive Organization

GE Healthcare Holdings, Inc.GE Healthcare, Inc.GE Healthcare Ltd. (United Kingdom)

+ [1]

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Structure

Molecular FormulaC33H40I6N6O15

InChIKeyBFVVDRUCXCIALU-UHFFFAOYSA-N

CAS Registry1095110-48-7

Clinical Trials associated with Ioforminol

JPRN-JapicCTI-142517 / Unknown statusPhase 2

A phase 2, double-blind, randomized, safety and efficacy study of GE-145 versus Iodixanol in subjects undergoing cerebral angiography.

Start Date01 May 2014

Sponsor / Collaborator-

JPRN-JapicCTI-142518 / Unknown statusPhase 2

A phase 2, double-blind, randomized, safety and efficacy study of GE-145 versus Iodixanol in subjects undergoing peripheral angiography.

Start Date16 Apr 2014

Sponsor / Collaborator-

JPRN-JapicCTI-132391 / Unknown statusPhase 2

A phase 2, double-blind, randomized, safety and efficacy study of GE-145 versus Iohexol in subjects undergoing coronary angiography.

Start Date01 Nov 2013

Sponsor / Collaborator-

100 Clinical Results associated with Ioforminol

100 Translational Medicine associated with Ioforminol

100 Patents (Medical) associated with Ioforminol

Literatures (Medical) associated with Ioforminol

01 Nov 2010·Acta RadiologicaQ4 · MEDICINE

GE-145, a new low-osmolar dimeric radiographic contrast medium

Q4 · MEDICINE

Article

Author: Evans, Paul ; Hagelin, Gunnar ; Rasmussen, Henrik ; Roed, Line ; Thaning, Mikkel ; Rogstad, Astri ; Grant, Derek ; Gram, Andreas ; Wistrand, Lars-G. ; Oulie, Inger ; Newton, Ben ; Iveson, Peter

Background: Contrast-induced nephrotoxicity is a significant risk when using radiographic contrast media clinically, especially in high risk patients. Consequently, there is a need for a new contrast agent with improved clinical safety with regards to nephrotoxicity. Purpose: To evaluate the physicochemical properties as well as the preclinical safety and biodistribution parameters of the newly developed radiographic contrast medium GE-145. Material and Methods: Standard methods for radiographic contrast media were used for evaluation of physicochemical properties. The acute toxicity in rats was studied at 8, 10, and 12.5 gI/kg, the clinical chemistry parameters were determined, and histology of the kidneys was performed. Biodistribution was studied in rats using 123I-labeled GE-145. Results: GE-145 is more hydrophilic than iodixanol and has a considerably lower osmolality. The viscosity is similar to that of iodixanol and the protein binding is low. The acute toxicity is similar to that of iodixanol and the biodistribution is similar to that of other radiographic contrast media, showing mainly renal excretion. Kidney histology showed a moderate reversible vacuolization, similar to that of iodixanol. Conclusion: GE-145 exhibits similar preclinical properties to other dimeric radiographic contrast media. In addition, the low osmolality enables an iso-osmolar formulation containing a significantly higher concentration of electrolytes than Visipaque.

01 Nov 2010·Acta RadiologicaQ4 · MEDICINE

Predicting cardiotoxicity propensity of the novel iodinated contrast medium GE-145: Ventricular fibrillation during left coronary arteriography in pigs

Q4 · MEDICINE

Article

Author: Rasmussen, Henrik ; Hvoslef, Anne-Marie ; Newton, Ben B. ; Chai, Chun-Ming ; Eriksen, Morten ; Videm, Signe ; Evans, Paul

Background: Severe side effects caused by iodinated radiographic contrast media (CM) are rare, but can occur in high risk patients and during percutaneous coronary intervention. To minimize this risk a new nonionic CM with low inherent osmolality has been designed, giving room for a relatively high concentration of favorable electrolytes in the isotonic formulation. Purpose: To test a new radiographic CM (GE-145) in a pig model of cardiotoxicity by comparing its ventricular fibrillation (VF) propensity and hemodynamic effects to that of iodixanol. Material and Methods: Test agents were injected into the left anterior descending coronary artery (LAD) of pigs through an inflated balloon catheter (injection volume 25 ml, injection rate 0.4 ml/s, maximum injection time 62.5 s). Series 1: GE-145 (338 mg I/ml) + 45 mM NaCl and iodixanol (321 mg I/ml) + 19 mM NaCl were injected in five pigs. Series 2: GE-145 (320 mg I/ml) + 45 mM NaCl + 0.1, 0.3, or 0.7 mM CaCl2 and iodixanol (320 mg I/ml) + 19 mM NaCl + 0.3 mM CaCl2 (Visipaque) were injected in six pigs. Results: Iodixanol + NaCl caused VF in 6 of 13 injections (46%) after 60.3±7.5 s (mean ± SD). GE-145 + NaCl did not cause any VF in 13 injections (0%) ( P<0.05). Iodixanol + 19 mM NaCl + 0.3 mM CaCl2 caused VF in 9 of 9 injections (100%) after 61±4 s. GE-145 + 45 mM NaCl + 0.1, 0.3, or 0.7 mM CaCl2 did not cause any VF during or after 9 injections of each agent (0%) ( P<0.05). The least hemodynamic effects were seen with GE-145 + 45 mM NaCl + 0.7 mM CaCl2. Conclusion: In this model of direct administration of CM into the LAD of anesthetized pigs, the tested GE-145 formulations had a significantly lower propensity to induce VF than iodixanol with electrolytes. Favorable hemodynamic properties of GE-145 can be achieved by optimizing concentrations of sodium and calcium.

100 Deals associated with Ioforminol

External Link

KEGG	Wiki	ATC	Drug Bank
D10475	-	-	DB12439

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Kidney Diseases	Phase 2	US	GE Healthcare Holdings, Inc.	01 Nov 2010
Diabetes Mellitus	Phase 2	US	GE Healthcare Holdings, Inc.	01 Nov 2010
Heart Failure	Phase 2	US	GE Healthcare Holdings, Inc.	01 Nov 2010
Vascular Diseases	Phase 2	-	GE Healthcare, Inc.	-
Vascular Diseases	Phase 2	US	GE Healthcare Ltd. (United Kingdom)	-
Vascular Diseases	Phase 2	JP	Daiichi Sankyo Co., Ltd.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01252810 (CTgov)	Phase 2	Diabetes Mellitus \| Heart Failure \| Chronic Kidney Diseases	284	GE-145	zfrsvjnjgn(evzrhehsga) = phgzdpfuhv sbnyqdmzdu (kzbhocvgkt, ijrphpgjsa - vbfeajheor) View more	-	02 May 2014
NCT01004770 (CTgov)	Phase 1/2	-	50	GE-145 (GE-145 Injection-300mg of Iodine/mL)	uezexmjhns(zqmpiztjyf) = ueeidwrpgg exurpuixgc (jleszgdjzm, zmkojokvke - elndtknvzv) View more	-	04 Apr 2012
NCT01004770 (CTgov)	Phase 1/2	-	50	GE-145 (GE-145 Injection-450mg of Iodine/mL)	uezexmjhns(zqmpiztjyf) = ncqzohgqvk exurpuixgc (jleszgdjzm, preabjjvdj - qiqnipfaqy) View more	-	04 Apr 2012

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis